Monday

Chairs: Chris Cannon (US), Sam Dagogo-Jack (US) Faculty: David Cherney (CAN), Ildiko Lingvay (US) 14:30 – 14:35 Opening Remarks Chairs 14:35 – 14:45 Ertugliflozin and VERTIS CV – New Data Expanding Our Understanding for the Treatment of Patients With Type 2 Diabetes and Cardiovascular Disease Sam Dagogo-Jack (US) 14:45 – 14:55 Recent Data on the Efficacy and Safety of Ertugliflozin Using Insulin in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease Ildiko Lingvay (US) 14:55 – 15:05 The Latest VERTIS CV Heart Failure Results – Adding to Our Clinical Understanding From a Cardiologist’s View 15:05 – 15:15 New VERTIS CV Kidney Protection Results – Adding to Our Clinical   Understanding From a Nephrologist’s View David Cherney (CAN) 15:15 – 15:28 What Does It All Mean For Our Patients? A Cross-Specialty Faculty Roundtable Discussion Faculty 15:28 – 15:30 Closing Remarks Chairs

Program Chair’s Introduction and Welcome
Applying Sensor‐Based Technology to Optimize Blood Glucose Time-in-Range (TIR) and Health Metrics Across the Comprehensive Spectrum of Diabetes Care: Establishing a New, Guideline- and Evidence-Based Standard of Care for Persons with Diabetes

Session 1
Applying Sensor-Based Glucose Monitoring and Telemedicine to Optimize Real World Impact and Diabetes Management in the Age of Covid-19 and Beyond—What Have the Studies Taught Us? How Do We Apply Them to Diabetes Practice Now?

Session 2
A Practical Roadmap for Using Registry Data and Trial-Based Evidence to Guide Use of Sensor‐Based, Glucose Monitoring: Focus on Results from National Diabetes Registries (NDRs) to Optimize Multi-Dose Insulin (MDI) Therapy in Persons with Diabetes

Session 3
Translating Guidelines and Meta‐Analysis Trials to Guide Practical Aspects of Diabetes Care: Using Sensor-Based Glucose Monitoring to Improve Time in Range (TIR), GMI and AGP for Persons with Diabetes on Non-Insulin Regimens

Program Chair’s Summary and Vision Statement
The Foundational Role of Sensor‐Based Glucose Monitoring Technology — How Should Clinicians and Patients Collaborate to Maximize Blood Glucose Time in Range and Improve Safety and Health Outcomes in Persons with Diabetes?

Chair: Jiten Vora (UK)
Co-Chair: Nayyar Iqbal (AstraZeneca)

14:30  – 14:35

Welcome

Elisabeth Björk (AstraZeneca)
Jiten Vora (UK)
Nayyar Iqbal (AstraZeneca)

14:35  – 14:50

Role of water conservation and metabolism in SGLT2 inhibitor mediated organ protection

Jens Marc Titze
(Singapore)

14:50  – 15:10

Cracking the code in CKD: Mechanisms of renoprotection

Hiddo Heerspink
(Netherlands)

15:10  – 15:30

SGLT2 inhibitors in HF: Piecing together the puzzle of preserved ejection fraction

Sanjiv Shah (USA)

15:30  – 15:40

Panel discussion

All faculty

15:40  – 15:55

State of art lecture:  NASH, disease burden and new opportunities – Emerging new modalities to manage NASH

Arun Sanyal (USA)

15:55  – 16:00

Closing remarks

Regina Fritsche-Danielson (AstraZeneca)
Jiten Vora (UK)

14:30 – 14:35

Welcome

Chair: Tina Vilsbøll (Denmark)

14:35 – 14:47

Should we have a more holistic treatment approach to improve healthy lifespan in people living with T2D?

Vanita Aroda (USA)

14:47 – 15:10

Panel discussion

Vanita Aroda (USA)
Melanie Davies (UK)
John Buse (USA)
Nikolaus Marx (Germany)

15:10 – 15:20

Treatment intensification in T2D with high-dose semaglutide: SUSTAIN FORTE

Juan Pablo Frias (USA)

15:20 – 15:25

Questions from the audience

 

15:25 – 15:27

Welcome back

Chair: Tina Vilsbøll (Denmark)

15:27 – 15:35

The potential of semaglutide 2.4 mg for weight management

Rachel Batterham (UK)

15:35 – 15:45

Changing the paradigm in obesity care: the STEP 1–4 data

Melanie Davies (UK)

15:45 – 15:55

The clinical impact of double-digit weight loss

John Wilding (UK)

15:55 – 16:08

Questions from the audience

 

16:08 – 16:10

Thanks and wrap-up

Chair: Tina Vilsbøll (Denmark)

16:30 – 16:35

Welcome

Chair: Tina Vilsbøll (Denmark)

16:35 – 16:45

Insulin innovations – the past: journey so far

Andreas Liebl (Germany)

16:45 – 16:55

Insulin innovations – the present: current scenario

Lena Landstedt-Hallin (Sweden)

16:55 – 17:05

Patient case study

Andreas Liebl (Germany)

Lena Landstedt-Hallin (Sweden)

17:05 – 17:20

Insulin innovations – the future: roadmap to the future

Ronald Goldenberg (Canada)

17:20 – 17:28

Panel discussion

 

17:28 – 17:30

Thanks and wrap-up

Chair: Tina Vilsbøll (Denmark)

19:00 – 19:05

Welcome

Chair: Tina Vilsbøll (Denmark)

19:05 – 19:30

Highlights and learnings: current diabetes and obesity management and future opportunities

Tuesday

09:15 – 09:20

Overview of oral semaglutide and PIONEER trials

Filip K Knop (Denmark)

09:20 – 09:30

Case scenarios based on clinical evidence

Filip K Knop (Denmark)
Vanita Aroda (USA)

09:30 – 09:35

Patient-centric practicalities

Vanita Aroda (USA)

09:35 – 09:45

A patient-centered approach with oral semaglutide

Panel discussion and Q&A (live)

 

17:40 – 17:45

The case challenge
Teaming up to tackle cardiorenal risk in diabetes

Melanie Davies (UK)

17:45 – 17:55

Defining treatment goals: SGLT2i, implications from clinical trials and guidelines

Nikolaus Marx (Germany)

17:55 – 18:05

Practical Challenges: SGLT2i in the spectrum of diabetes, CVD & CKD: Who and how to manage?

Melanie Davies (UK)

18:05 – 18:10

Discussion How to overcome clinical inertia?

Nikolaus Marx (Germany)
Melanie Davies (UK)

PACE-CME

 

 

Educational objectives

  • To summarise the epidemiology and pathophysiology of patients with diabetes, CVD and CKD
  • To discuss the role of SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiorenal risk
  • To address the remaining questions on the role of SGLT2 inhibition in the management of patients with diabetes and cardiorenal complications
  • To provide an expert perspective on the clinical management of patients with type 2 diabetes, CKD and CV

17:40 – 17:55

Introduction:
obesity, weight loss and CV risk

Kim Connelly (Canada)

17:55 – 18:10

STEPping forward:
cardiovascular risk factors in patients with overweight or obesity

Ildiko Lingvay (USA)

18:10 – 18:25

STEPping into the future:
managing cardiovascular outcomes in people with overweight or obesity

Subodh Verma (Canada)

18:25 – 18:40

Live Q&A

Chaired by Kim Connelly (Canada)

Speakers:                    

  • Associate Professor Neale Cohen FRACP
    Head Clinical Diabetes
    Baker Heart and Diabetes Institute
  • Dr Martin de Bock FRACP PhD
    Paediatric Endocrinologist
    University of Otago and Canterbury District Health Board

SUPPORT STATEMENT:
Supported by a Medical Education Grant from Gan & Lee

Chairs:
Vilsbøll, Tina (Denmark)
Heinemann, Lutz (Germany)

19:30 – 19:33IntroductionVilsbøll, Tina (DNK)
19:33 – 19:43Biosimilar Insulin Manufacturing:
Why the process IS the product?
Heinemann, Lutz (GER)
19:43 – 19:53Why do patient and HCP perceptions about
biosimilar insulin matter?
Home, Philip (UK)
19:53 – 20:00Discussion and closureAll

Wednesday

18:30 – 18:32

Welcome

Athena Philis-Tsimikas (USA)
Simon Heller (UK)

18:32 – 18:35

A retrospective look:
100 years since insulin was discovered

Simon Heller (UK)

18:35 – 18:47

Once-weekly basal insulins:
From innovation to RCTs

Athena Philis-Tsimikas (USA)

18:47 – 18:53

Patient-centric care:
How once-weekly options may help get patients to target

Simon Heller (UK)

18:53 – 18:58

Questions from the audience

Facilitated by:

Athena Philis-Tsimikas (USA)
Simon Heller (UK)

18:58 – 19:00

Wrap-up

Athena Philis-Tsimikas (USA)
Simon Heller (UK)

Description:
Four experts in primary care, endocrinology, cardiology and nephrology will come together to discuss a patient-centred and evidence-based approach to care in T2D after metformin, offering their clinical perspectives on the optimal and multifactorial management of an evolving patient case

Faculty:

  • John Buse (chair, USA)
  • Kate Stevens (UK)
  • Nikolaus Marx (Germany)
  • Naresh Kanumilli (UK)

Chairs: Ofri Mosenzon (ISRAEL), Rich Pratley (US)

Faculty: Chris Cannon (US), David Cherney (CAN)

18:30- 18:33                Opening Remarks

(3 min)                        Speakers: Chairs (US)

 

18:33-18:41                  ‘Highlighting the Patient with Diabetes and Cardiometabolic Disease’

(8 min)                        Speaker:  Rich Pratley (US)

 

18:41 – 18:49              ‘Answering Unmet Needs – Clinical Understanding of Recent Heart Failure Data for Patients with Diabetes and Cardiovascular Disease’

(8 min)                        Speaker: Chris Cannon (US)

 

18:49 -18:57                ‘Adding to the Clinical Understanding for Patients with Diabetes and Cardio-renal Disease’

(8 min)                        Speaker: David Cherney (CAN)

 

18:57 – 19:27              ‘A Cross-Specialty Faculty Roundtable on Meeting the Needs of Patients with Diabetes and Established Cardiometabolic Disease: Are SGLT2is Best Utilized as a Cardiovascular Drug? A Kidney Drug? A Glycemic Lowering Agent? Or All of the Above?’

(30 Min)                      Speakers: Faculty

 

19:27 – 19:30              Closing Remarks

(3 min)                         Chairs

SUPPORT STATEMENT:
Supported by an unrestricted educational grant from Amarin Pharma, Inc.

18:30 – 18:35

Welcome, Introductions, Program Overview

Dirk Müller-Wieland

18:35 – 18:55

New Clinical Evidence of Omega-3 Fatty Acids on ASCVD Event Reduction

Dirk Müller-Wieland

18:55 – 19:15

Real-world Clinical Implications on Reducing ASCVD Events

Handrean Soran

19: 15 – 19:30

Panel Discussion and Q&A

Handrean Soran

Dirk Müller-Wieland

Closing Comments

Dirk Müller-Wieland
Handrean Soran

Learning Objectives

At the conclusion of this activity, learners should be better able to:

  • Describe the spectrum of large-scale outcomes trials of omega-3 fatty acids on ASCVD events.
  • Appreciate the differences between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements.

Chair: Jiten Vora (UK)

Speakers: TBC

Time (CEST)

Title

Speaker

18:30–18:35
(5 min)

Welcome and introductions

Jiten Vora

18:35–18:45
(10 min)

Addressing unmet needs in CKD and T2D with nonsteroidal MR antagonists

TBC

18:45–19:00
(15 min)

MR antagonism confers benefits irrespective of anti-diabetic agents or metabolic status: Insights from FIDELIO-DKD

TBC

19:00–19:15
(15 min)

FIGARO-DKD: Expanding the benefit of MR antagonism in CKD and T2D

TBC

19:15–19:25
(10 min)

Q&A

All faculty

19:25–19:30

(5 min)

Summary and close

Jiten Vora

Chair – Prof Matthias Laudes

Speakers – Prof Francesco Giorgino, Prof Vaia Lambadiari

 

Agenda:

  • Welcome and introduction (Prof Matthias Laudes)
  • Diagnosis of severe insulin resistance and atypical diabetes and when to suspect lipodystrophy (Prof Francesco Giorgino)
  • The management of lipodystrophy: clinical challenges and treatment opportunities (Prof Vaia Lambadiari)
  • Q&A, conclusions (Prof Matthias Laudes)

Thursday

09:15 – 09:35

How and why to identify high-risk patients: lessons from the clinic

Elmar Jaeckel (Germany)
Lise Lotte Gluud (Denmark)

09:35 – 09:45

The future of NASH: the importance of interdisciplinary collaboration (interactive Q&A)

Elmar Jaeckel (Germany)
Lise Lotte Gluud (Denmark)

Faculty:  David Cherney (CAN), Kim Connelly (CAN), Samuel Dagogo-Jack (US)

18:15- 18:20                Opening Remarks

(5 min)                        Speaker: Sam Dagogo-Jack (US)

 

                                   

18:20 – 18:43              ‘Cross-talk between the Heart, Kidneys & the Endocrine System – Understanding

(23 min)                       for Type 2 Diabetes and Cardiorenal Disease’                    

                                   

Speakers: David Cherney (CAN), Kim Connelly (CAN), Samuel Dagogo-Jack (US)

18:43- 18:45               Closing Remarks

(2 min)                        Speaker: Sam Dagogo-Jack (US)

SUPPPORT STATEMENT
Supported by an independent educational grant from Novo Nordisk.

TARGET AUDIENCE
This activity is intended for diabetologists/endocrinologists, primary care physicians and cardiologists.

18:15 – 18:30

The Endocrinologist in the Lead

The Right Drug for the Right Patient at the Right Time

18:30 – 18:45

The Cardiologist in the Lead

Primary and Secondary Cardiovascular Protection

18:45 – 19:00

The Primay Care Physician in the Lead

Implementing Proactive Diabetes Care across the Stages

19:00 – 19:15

Panel Discussion and Q & A

19:15

Adjourn

Friday

SUPPPORT STATEMENT
Supported by an independent educational grant from Lilly.

TARGET AUDIENCE
This activity is intended for diabetologists/endocrinologists and PCPs

08:15 – 08.25

Better Metabolic Health with Incretin-based Therapies – Achievements and Ambitions

08:25 – 08:40

The Power of novel dual GIP/GLP-1 Receptor Agonists 

08:40 – 09:00

The Clinical Evidence for GIP/GLP-1 Receptor Agonists – Assessing the Emerging Profile

09:00 – 09:15

Panel Discussion and Q & A

09:15

Adjourn

17:40 – 17:43

Welcome

Adie Viljoen (UK)

17:43 – 17:51

Early treatment: what are the benefits of early initiation of GLP-1RAs?  

Tina Vilsbøll (Denmark)
Juris Meier (Germany)

17:51 – 18:01

Discussion session 1

Tina Vilsbøll (Denmark)
Juris Meier (Germany)

18:01 – 18:09

Spotlight on: type 2 diabetes management for those with renal impairment

Tina Vilsbøll (Denmark)
Peter Rossing (Denmark)

18:09 – 18:19

Discussion and Q&A

Tina Vilsbøll (Denmark)
Peter Rossing (Denmark)

18:19 – 18:27

Spotlight on: glycaemic management in individuals with T2D and CVD

Matt Cavender (USA)
David Strain (UK)

18:27 – 18:37

Discussion session 2

Matt Cavender (USA)
David Strain (UK)

18:37 – 18:40

A look at what is up and coming

Adie Viljoen (UK)